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Summary
Osteoarthritis (OA) research is beginning to focus on developing structure (disease) modifying treatments that will stabilize or reverse
morphological changes, thereby altering the underlying pathologic process. The ability of anti-arthritic agents to modify the course of disease
has been investigated in a limited number of clinical trials. Agents studied in published clinical trials include glycosaminoglycan-peptide
complex (GP-C), glycosaminoglycan polysulfate (GAGPS), diacerein, and glucosamine sulphate. These clinical trials have been difficult to
interpret and compare because the patients studied are often inadequately characterized or are not comparable across studies. Studies also
vary with respect to the outcome measures analyzed and the methodology applied to measurement and data analysis. Further, in general,
the rate of radiographic progression of OA is slow and is not consistent across populations and patients with varying disease severity. In man,
the radiograph has been the gold standard for evaluating treatments. Further longitudinal validation of the radiograph is needed. As
techniques improve, variation in the system and the number of patients needed in studies are decreasing. It may be that the radiograph will
not achieve the needed degree of validation and will be supplanted by magnetic resonance imaging as the surrogate marker of joint status.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Structure modifying treatments for osteoarthritis
Currently available treatments for osteoarthritis (OA) com-
bine nonpharmacologic and pharmacologic regimens
directed toward relief of symptoms. At present, no drugs or
devices have been consistently shown to modify joint
structure or reverse joint pathology. Nevertheless, con-
siderable research is now being focused on structure
modification. The objective of structure modifying therapies
is to prevent, stabilize or reverse the morphological
changes of the cartilage in OA, thereby altering the under-
lying pathologic process. These treatments may or may not
have an independent effect on symptoms. Disease-
modifying therapies include anti-inflammatory drugs, anti-
osteoclastic agents, cytokines/growth factors, enzyme
inhibitors, gene therapy, non-sulfated glycosaminoglycans,
a variety of sulfated sugars, and stem cell/transplantation.
Demonstration of the benefits of treatment will depend
upon the trial design and outcome parameters selected.
Disease classification
Clinical trials of OA therapies are difficult to interpret and
compare because the patients studied are from different
populations, are often inadequately characterized or are
not comparable across studies. Some years ago, a check
list for classification of OA of the knee based on the results
of clinical examination, laboratory tests, and radiographs
was proposed (Table I)1. According to this system, patients
are classified as having OA if they have knee pain and
radiographic osteophytes. Knee pain cannot be referred
and has to be present for most days of the prior month. In
the absence of osteophytes, patients are classified as
having OA if they have knee pain, a synovial fluid
examination consistent with OA, morning stiffness of
30 min or less, and crepitus on active motion. In patients
for whom synovial fluid has not been examined, age of
40 years or older can be used as a surrogate for the
synovial fluid criterion. This check list has been shown
to have a sensitivity of 94% and a specificity of 88%.
Although, these criteria are useful for classification of
disease and may not be specific enough for use in selecting
patients for trials of structure-modifying agents. Selection of
a well-characterized subset of patients makes possible
detection of differences between treatment groups that may
not be apparent in studies of less well-defined populations.
Most commonly, patients with OA are classified into
2 subgroups: patients with primary or idiopathic OA, in
whom no known prior event or disease is related to the OA,
and patients with secondary OA, in whom no known event
or disease is related to OA. The subclassification criteria
proposed by the American College of Rheumatology are
presented in Table II1,2. Primary or idiopathic OA is sub-
divided according to whether it is localized or generalized.
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Table I
Checklist for classification of osteoarthritis of the knee (adapted
from Reference1 with permission from W.B. Saunders Company.)
Knee pain (most days of prior month)
+ Major
Radiographic osteophyte
+ Minor criteria
Synovial fluid (SF) findings consistent with osteoarthritis
(age ≥40 years can be used as surrogate for SF if SF is not
examined)
Morning stiffness (<30 min)
Crepitus (active motion)
Sensitivity 94% Specificity 88%
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Disease may be localized to the hands, feet, knees, hips,
spine, or virtually any other articulation. Generalized dis-
ease may involve small joints, large joints, or a mix of the
two with spinal involvement. Secondary OA is subdivided
by etiology or associated condition or disease. OA may be
secondary to trauma, congenital/developmental abnormali-
ties, calcium deposition, bone and joint disorders, or other
conditions, such as endocrine or neurogenic abnormalities.
Although many trials are designed to enroll patients with
primary or idiopathic OA, these trials often include patients
with OA secondary to one or more factors. In such cases, it
is difficult to determine the influence of such factors on the
study population and the response to treatment. Although
studies of broadly defined patient populations allow study
conclusions to be generally applied, wide variability across
the patients studied increases the sample size of the study
population needed to show statistically significant differ-
ences between treatment groups and may prevent the
recognition of subsets of patients who may benefit from
treatment unless extensive stratification is performed.
Outcome measures in arthritis clinical trials
Advances in the diagnosis and treatment of OA have led
to re-evaluation of the outcome measures and measure-
ment procedures used in clinical studies of OA. Guidelines
for clinical studies of the effects of OA therapies have been
published by a number of individuals and groups in the last
decade3–5. The Outcome Measures in Arthritis Clinical
Trials (OMERACT) group recommended a core set of
outcome measures for future phase III clinical trials of
knee, hip, and hand OA6. It was determined that 4 core
domains should be evaluated: pain, physical function,
patient global assessment, and joint imaging (for studies of
≥1 year). Secondary outcome measures (strongly recom-
mended) included health-related quality of life measures
and physician global assessment. Tertiary outcome
measures (optional) included measures of stiffness, bio-
logic markers, measures of inflammation, performance-
based measures, flares, time to surgery, and analgesic
consumption.
Table II
The American College of Rheumatology Classification for Subsets of Osteoarthritis (Reprinted from Reference1 with permission from W.B.
Saunders Company.)
I. Idiopathic
A. Localized
1. Hands: Heberden’s and Bouchard’s nodes (nodal), erosive interphalangeal arthritis (nonnodal), scaphometacarpal joint,
scaphotrapezial
2. Feet: hallux valgus, hallux rigidus, contracted toes (hammer/cockup toes), talonavicular
3. Knee
a. Medial compartment
b. Lateral compartment
c. Patellofemoral compartment (chrondromalacia)
4. Hip
a. Eccentric (superior)
b. Concentric (axial, medial)
c. Diffuse (coxae senilis)
5. Spine (particularly cervical and lumbar)
a. Apophyseal
b. Intervertebral (disc)
c. Spondylosis (osteophytes)
d. Ligamentous (hyperostosis [Forestier’s disease or diffuse idiopathic skeletal hyperostosis])
6. Other single sites: shoulder, temporomandibular, sacroiliac, ankle, wrist, acromioclavicular
B. Generalized: includes 3 or more areas listed above (Kellgren-Moore)
1. Small (peripheral) and spine
2. Large (central) and spine
3. Mixed (peripheral and central) and spine
II. Secondary
A. Posttraumatic
B. Congenital or developmental diseases
1. Localized
a. Hip diseases: Legg-Calve-Perthes, congenital hip dislocation, slipped capital femoral epiphysis, shallow acetabulum
b. Mechanical and local factors: obesity (?), unequal lower extremity length, extreme valgus/varus deformity, hypermobility
syndromes, scoliosis
2. Generalized
a. Bone dysplasias: Epiphyseal dysplasia, spondyloapophyseal dysplasia
b. Metabolic diseases: hemachromatosis, ochronosis. Gaucher’s disease, hemoglobinopahty, Ehlers-Danlos
C. Calcium deposition disease
1. Calcium pyrophosphate deposition disease
2. Apatite arthropathy
3. Destructive arthropathy (shoulder, knee)
D. Other bone and joint disorders: avascular necrosis, rheumatoid arthritis, gouty arthritis, septic arthritis, Paget’s disease, osteo-
petrosis, osteochondritis
E. Other diseases
1. Endrocrine diseases: diabetes mellitus, acromegaly, hypothyroidism, hyperthyroidism
2. Neuropathic arthropathy (Charcot joints)
3. Miscellaneous: e.g., frostbite, Kashin-Beck disease, Caisson disease
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The Osteoarthritis Research Society (now the Osteo-
arthritis Research Society International) also established a
Task Force to address the issue of clinical trial guidelines
for OA, and in 1996, this group published a set of recom-
mendations for the design and conduct of clinical trials in
patients with OA7. These recommendations addressed
trials of both symptom-modifying drugs and structure-
modifying drugs. The guidelines recommend that for
studies of potential structure modifying drugs the primary
outcome variable should be a measure of joint morphology
obtained through imaging techniques or direct visualization
(i.e., arthroscopy). Currently, time to joint replacement
surgery is not recommended as a primary outcome variable
because it appears, at least in part, on factors that are
unrelated to disease progression. Patients participating in
trials of structure modifying drugs should be evaluated
at intervals of about 3 months. Imaging modalities may
consist of radiography or magnetic resonance imaging.
Computed tomography, ultrasonography, and scintigraphy
are other available imaging modalities, but these have not
been adequately validated and are not therefore recom-
mended for use in long-term studies. Molecular markers
continue to be an area of intense research but have not yet
been validated as outcome measures in clinical trials of
OA. Arthroscopy measures surface changes of cartilage.
Although standardization techniques have been proposed,
they have not been uniformly accepted8.
Problems related to imaging studies
There are multiple problems related to imaging studies.
Obtaining reproducible images at successive visits is
critical to reliably assess progression of OA. There are
numerous sources of variability associated with measure-
ment of joint space width on radiographs, including differ-
ences in patient positioning, radiographic procedures,
measurement processes, and reading techniques, as well
as inter-reader and intra-reader variability. Even digitized
computer techniques may present problems in terms of
how landmarks are identified, where the narrowest point is
measured, what is meant by volume, etc. There are also
problems associated with magnetic resonance imaging,
including variability in patient positioning, precision of
measurement, coefficient of variability, and validation of
ability to demonstrate change. Long-term studies present a
challenge in that the methodology specified in the protocol
at the start of the study must be used throughout the trial,
even though technological advances lead to dramatic
improvements in state-of-the-art methodology as the study
progresses9,10. Studies that adhere to the protocol through-
out their duration are usually criticized for not using the
most current imaging methods – even though the most
current imaging technique was not the standard at the time
the study was initiated.
Radiographic progression of knee osteoarthritis
in patients receiving only physical therapy and
nonsteroidal anti-inflammatory drugs
Pavelka et al.10 conducted a study to determine the
5-year radiographic progression of OA of the knee in a
cohort of 139 patients with idiopathic OA who received only
physical therapy and nonsteroidal anti-inflammatory drugs
(NSAIDs) as needed. This cohort was the control group for
a trial described later. Radiographs were taken at baseline
and at the final assessment and evaluated according to the
Kellgren-Lawrence (K-L) scale11, and joint space width was
measured according to the Lequesne technique12. After
5 years, the overall mean change in joint space width was
0.39±0.95 mm, representing a mean change of 0.078±
0.19 mm per year. The progression in joint space reduction
was not linear, being most rapid in the first year. The
smallest reductions in joint space width were noted in
patients in K-L class 0 or 1, while the greatest reductions in
joint space width were noted among patients in K-L class 0
or I, while the greatest reductions in joint space width were
noted among patients in K-L class III. Overall, 25% patients
had progression of disease, with the highest percentages
of patients with progression in K-L classes II (25%) or III
(26.8%). Hence, changes in joint space width were small
and occurred in only a quarter of the patients over a 5-year
period. This slow progression raises the issue of the value
of examining progression of joint space narrowing in a
general OA population by this technique.
Studies of structure (disease) modifying agents
The ability of anti-arthritis agents to modify the course of
disease in man has been investigated by a limited number
of trials. Agents studied include glycosaminoglycan-peptide
complex (GP-C, Rumalon®; Robapharm, Ltd, Basel,
Switzerland) and glycosaminoglycan polysulfate (GAGPS;
Arteparon®, Luitpold-Werk, Munich)9,13,14; diacerein15; and
glucosamine sulphate16.
GP-C AND GAGPS
In the early 1960s, Rejholec and colleagues14 performed
a 10-year, randomized, placebo-controlled study to
evaluate the long-term therapeutic effect of GP-C in
patients with OA of the hip. The population evaluated
consisted of 112 pairs of patients with OA of the hip
matched for age, sex, weight, physical stress, joint involve-
ment, and radiologic stage of the disease according to the
K-L classification11. One member of each pair received
GP-C 1 mL injected twice weekly; these patients received 2
series of 25 injections yearly. The second member of each
pair (control) received vitamin B12 0.1 mg twice a year.
At the start of treatment, 52 patients in the control group
and 52 in the GP-C group had K-L X-ray grades I or II
(Fig. 1). At the 10-year follow-up, K-L grades of I or II
persisted in 29% of the patients in the control group and in
60% of those in the GP-C group. Sixty patients in the
control group and 60 in the GP-C group had K-L X-ray
grades III and IV at the start of treatment. At the 10 year
follow-up, the number of patients with K-L grades III and IV
had increased to 68 (113%) in the control group and had
decreased to 52 (87%) in the GP-C group. The severity
grade of OA in the GP-C group was significantly lower than
in the control group (P<0.005). Joint space width,
measured in the standing position, could be compared in
35 pairs of patients after 16 years of treatment. There was
significantly less narrowing in the GP-C group (−47%) than
in the control group (−75%) (P<0.05). Total hip replacement
was needed in 17 patients in the control group, compared
with only 6 in the GP-C group (P<0.05). The investigators
concluded that the study showed the therapeutic value of
treatment with GP-C in OA of the hip.
Nevertheless, the study was criticized on the basis of
reproducibility, the applicability of its findings to other types
of OA (such as in hands and feet), and the possibility that
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different results could be found using more current
measurement techniques. As a consequence, Rejholec
et al. performed a study comparing GP-C and GAGPS with
standard therapy14.
The second study was a placebo-controlled trial in 147
patients ≥55 years of age, with K-L grades II and III.
Patients received symptomatic treatment (control group),
GP-C 1 ml injected twice weekly for 12.5 weeks of each
6-month interval over a 5-year period plus symptomatic
treatment (GP-C group), or GAGPS 50 mg injected twice
weekly for 7.5 weeks of each 6-month interval over a 5-year
period plus symptomatic treatment (GAGPS group). Sub-
jective and objective parameters were measured at base-
line, monthly for 4 months, and then every second month
until completion of the study at 60 months (or until dis-
continuation). Patients had assessment of arthritic pain,
nocturnal pain, pain on maximum passive movement,
NSAID use, working days, knee circumference, maximum
flexion, walking time, sit/stand time, and time required for
climbing stairs, and physician’s global assessment. Radio-
graphs were assessed before entry into the trial and at
the end of the trial or after at least 36 months. The
roentgenologic criteria evaluated included joint space
width, tibial intercondylar eminences, osteophytes,
subchondral sclerosis and bone cysts, and marginal
defects and bone necroses. The number of surgical
interventions was also recorded, as were all side effects.
After 2 years of study, NSAID use increased in the
control group but decreased in the GP-C and GAGPS
groups. Improvements in symptoms and measures of joint
function and status were significantly greater in the two
active treatment groups than in the control group. Also,
quality of life and ability to work were markedly improved in
the two active treatment groups, and in some cases, were
better than at baseline. The frequency of surgical interven-
tions was also reduced in these two groups. Both GP-C
and GAGPS favorably affected radiographic findings. The
percentages of patients in the GP-C and GAGPS groups
with no progression of OA were seven and nine times
higher, respectively, than in the control group. At the end of
therapy, medial joint space widths were significantly less
in the active treatment groups than in the control group
(Fig. 2).
Pavelka et al.9 initiated further study of GP-C in OA in
response to questions concerning methodological issues
raised regarding the previous studies. This group con-
ducted a 5-year, randomized, placebo-controlled, double-
blind study of GP-C to determine the structure (disease)
modifying effect of long-term therapy with GP-C in patients
with knee and hip OA9. In this study, 277 patients with knee
OA and 117 with hip OA received 15 intramuscular injec-
tions of GP-C or placebo twice weekly every 6 months for
5 years. NSAIDs and analgesics were permitted at the
discretion of the investigator. The outcome measures used
in this study were selected on the basis recommendations
of an external advisory group set up by the sponsor. The
primary outcome measure was changed in radiographic
joint space width from baseline to the final visit at 5 years.
Joint space width was measured by the method of
Lequesne17, with a ×10 magnifying lens marked with a
20-mm scale at 0.1 mm intervals. This technique was
reliable and easy to use. Secondary outcome measures
included pain, pain on passive motion, patient global,
investigator global, and NSAID consumption.
The drop out rate of this study was low; over 90% of
patients completed the study. The results of this trial
showed no difference in the progression of joint space
narrowing between the GP-C and control groups at the hip
or knee (Figs. 3 and 4). At the hip, the mean change in joint
space width was −0.22 mm in the placebo group, com-
pared with −0.21 mm in the GP-C group (difference not
significant). At the knee, the mean change in joint space
width was −0.42 mm in the placebo group, compared with
−0.37 mm in the GP-C group (difference not significant).
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Fig. 1. Results of long-term study of GP-C in 112 pairs of patients treated with GP-C and or vitamin B12 (control). K-L 1-2: JSW: Bars
represent percentage decrease from baseline in joint space width (JSW) after 16 years of treatment with GP-C (N=35) or vitamin B12 (control;
N=35). The change from baseline was significantly greater in the control group than in the GP-C group (P<0.05). THP: Bars represent the
number of patients in the GP-C group (N=112) and vitamin B12 (N=112) group who required total hip replacement (THP) over the course of
the 16-year study.
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Similarly, there was no difference between the groups in the
secondary outcome measures. Unfortunately, the study
population was too small to allow for adequate evaluation
of subsets of patients. However, in an examination of
patients with OA of the hip with joint space width ≥1 mm
baseline; noprogression occurred in the 25 patients on
GP-C, whereas progression occur in 4/21 (19%) patients in
the control group, and the difference approached signif-
cance. There are no adequate explanations for the differ-
ences between these findings and those reported earlier by
Rejholec. The findings may have differed because the
effects of GP-C were small, the measurements selected for
the study were not adequately sensitive to reveal differ-
ences between treatments, or the patient selection criteria
used in this study may have influenced the trial results.
DIACEREIN
Dougados et al.15 conducted a randomized, double-
blind, placebo-controlled, 3-year study to evaluate the
ability of diacerein, a possible interleukin-1 beta inhibitor, to
slow the progressive decrease in joint space width ob-
served in patients with hip OA. In this study, 507 patients
with primary OA of the hip received oral diacerein 50 mg
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Fig. 2. Degree of narrowing of medial joint space width in patients with knee OA who received symptomatic treatment only (control, N=42);
GP-C (N=47); or GAGPS (N=41). Mean values are expressed as scores: 0=normal to 5=joint cavity absent (based on data presented in
Rejholec, 1987).
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Fig. 3. Mean hip joint space width (mm) at baseline and at the end of treatment with placebo (N=59) or GP-C (N=58) and change (mm) from
baseline in hip joint space width at the end of treatment.
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twice daily or placebo. The primary end-point of the study
was the radiographic progression of OA as determined by
the change in joint space width from baseline to the final
evaluation.
The percentage of patients with radiographic progres-
sion, defined by a joint space narrowing of at least 0.5 mm,
was significantly lower in patients receiving diacerein than
in patients receiving placebo (51% in diacerein group
versus 60% in the placebo group; P=0.036). In those
patients who completed 3 years of treatment, the annual
rate of joint space narrowing was significantly lower in the
diacerein group (mean±SD 0.18±0.25 mm/year) than in the
placebo group (0.23±0.23 mm/year) (P=0.042) (Fig. 5).
Diacerein had no apparent effect on the symptoms of OA in
this study. The authors concluded that diacerein has a
significant structure-modifying effect in hip OA and can
retard the progressive decrease in joint space width in
affected patients.
GLUCOSAMINE SULPHATE
In a recent study, Reginster et al.16 assessed the effects
of glucosamine sulphate on the progression of OA joint
OA Knee: 5 yr study
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Fig. 4. Mean knee joint space width (mm) at baseline and at the end of treatment with placebo (N=139) or GP-C (N=138) and change (mm)
from baseline in knee joint space width at the end of treatment.
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Fig. 5. Percentage of patients treated with placebo (N=225) or diacerein (N=221) for 5-years who had radiographic progression (decrease
from baseline in joint space width of at least 0.5 mm).
S74 R. D. Altman: Measuring structure modification in OA
structure changes and symptoms in a randomized, double-
blind, placebo-controlled trial. In this study, 212 patients
with knee OA were assigned to receive glucosamine sul-
phate 1500 mg or placebo once daily for 3 years. Radio-
graphs were taken of each knee at enrolment and after 1
and 3 years. The primary outcome measure was mean
joint-space width of the medial compartment of the tibio-
femoral joint. Anteroposterior radiographs were taken with
the patient standing with the knee weightbearing and fully
extended. The patella was centralized over the lower end of
the femur by rotating the lower extremity. The feet were
placed a short distance apart, and foot maps were used to
re-position the patient. The X-ray beam was parallel to the
tibial plateau and fluoroscopically centered on the joint
space and parallel to the tibial plateau. Mean joint space
width was assessed automatically from digitized images. In
addition, changes in joint space width were confirmed by
the Lequesne visual method of inspection using a 0.1-mm
graduated magnifying glass18. Symptoms of OA were
assessed according to Western Ontario and McMaster
Universities (WOMAC) OA index.
In the intention-to-treat worst scenario analysis of all
randomized patients, after 3 years, a mean joint space loss
of −0.31 mm was observed in the placebo group, compared
with no significant joint space loss (−0.06 mm) in the
glucosamine sulfate group (placebo vs glucosamine sul-
fate, P=0.043). After 3 years, 32 (30%) of 106 patients in
the placebo group had a mean joint space narrowing of
more than 0.5 mm, compared with only 16 (15%) of 106 in
the glucosamine sulphate group (P=0.013) (Fig. 6). Com-
parisons of the changes from baseline in the primary
WOMAC scores showed that symptoms worsened slightly
in placebo-treated patients, whereas they improved in
the glucosamine sulfate group. The differences between
the mean changes from baseline in the placebo and
glucosamine sulphate groups were significant. The authors
concluded that administration of glucosamine sulphate
over 3 years can prevent structural changes in the joints of
patients with OA of the knee with a significant improvement
in symptoms. A possible limitation of this study is the use of
the radiographic views of the leg fully extended and weight-
bearing for assessment of structural changes. It has been
suggested that other views may avoid changes in patient
positioning that could result from changes in symptom
severity during the study. Patients whose symptoms dimin-
ish may achieve better knee extension and, as a result,
lower apparent joint space narrowing19. The findings from
this study appear to have been duplicated in a study by
Pavelka20.
Technical aspects of radiographic imaging
Posterior knee cartilage is thicker on the posterior
lateral aspect of the condyle, where most of the weight is
distributed, and not on the inferior aspect of the condyle,
which is reflected in straight leg weight bearing views. This
finding in cartilage is consistent with Wolff’s Law, which
holds that change in the form and function of bones is
followed by alterations in their conformation. Hence, an
X-ray of a partially flexed, weight-bearing knee is more
likely to reflect clinically relevant cartilage thickness.
During assessment joint space width, it should be noted
that in the tibial configuration in the medial compartment
there is a dip, causing the anterior and posterior lips of the
tibial plateau to have a double density on the X-ray. There
may be three levels seen: anterior lip, posterior lip and
trough of the dip. A fourth level of density often appears
from posterior tibial osteophytes. A superimposed anterior
and posterior lip is needed with an X-ray beam that runs
parallel to the tibial plateau. Fluoroscopic positioning, use
of a metal ball to adjust for magnification, and foot maps for
repositioning are some of the methods proposed for
improving consistency among X-rays that are obtained
months apart. Many studies are being conducted to
standardize the radiographic techniques. However, it may
be that newly developed techniques of magnetic resonance
imaging will replace the radiograph as the primary efficacy
variable in future structure modifying trials.
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Fig. 6. Percentages of patients treated with placebo (N=106) or glucosamine sulphate (GSO4) (N=106) for 3 years who had joint space
narrowing of more than 0.5 mm.
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Concluding comments
Very few trials have been completed to date that examine
the ability for an agent to alter the course of OA. All trials to
date have had difficulty because the primary end-point has
been hard to define and measure. In man, the radiograph
has been the gold standard, since examination of tissue
is not practical or ethical. Further longitudinal validation
of the X-ray is needed. As radiographic techniques are
improved, there is less variation in the system and fewer
patients are needed in studies. It may be that the radio-
graph will not achieve the needed degree of validation and
that magnetic resonance imaging will supplant it as the
surrogate marker of joint status.
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